← ANALYST RATINGS · TIPRANKS
Prothena (PRTA): analyst forecast and price target
Analyst consensus
Hold2 Buy1 Hold1 Sell
Ratings of 4 analysts in the last 3 months12-month forecast
Based on 4 price targets given in the last 3 months, the average target is $26.33, the highest $36.00, the lowest $13.00. The average is +215.4% from the last price of $8.35.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $9.50 | Hold | +13.8% | Reiterated | 09.09.26on TipRanks 00:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $9.50 | Hold | +13.8% | Reiterated | 09.09.26on TipRanks 00:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $9.50 | Hold | +13.8% | Reiterated | 09.09.26on TipRanks 00:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $9.50 | Hold | +13.8% | Upgrade | 09.09.26on TipRanks 00:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $9.50 | Hold | +13.8% | Reiterated | 09.09.26on TipRanks 00:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $9.50 | Hold | +13.8% | Reiterated | 09.09.26on TipRanks 00:05 | — | |
| Tazeen Ahmad★★★★★★★★★★#1537 · hits 60% · avg +5.8% | Bank of America Securities | — | Sell | — | Reiterated | 14.08.26on TipRanks 11:15 | −2.2%next day +0.7% · 5 days +8.0% | ↗ |
| Yasmeen Rahimi★★★★★★★★★★#160 · hits 51% · avg +36.0% | Piper Sandler | $36.00 | Buy | +331.1% | Reiterated | 07.08.26on TipRanks 11:27 | +1.5%next day +4.1% · 5 days +0.7% | ↗ |
| Andrew Fein★★★★★★★★★★#267 · hits 52% · avg +23.7% | H.C. Wainwright | $30.00 | Buy | +259.3% | Reiterated | 07.08.26on TipRanks 06:45 | +1.5%next day +4.1% · 5 days +0.7% | ↗ |
| Brian Abrahams★★★★★★★★★★#481 · hits 57% · avg +15.1% | RBC Capital | $13.00 | Hold | +55.7% | Reiterated | 06.08.26on TipRanks Aug 7 07:26 | +1.2%next day +1.5% · 5 days +4.6% | ↗ |
| Jason Butler★★★★★★★★★★#412 · hits 51% · avg +18.3% | Citizens JMP | $19.00 → $20.00+5.3% | Buy | +139.5% | Reiterated | 08.05.26on TipRanks 06:15 | +1.2%next day −10.1% · 5 days −9.2% | ↗ |
| Rudy Li★★★★★★★★★★#235 · hits 63% · avg +76.1% | Wolfe Research | $18.00 | Buy | +115.6% | Initiated | 31.12.25on TipRanks Jan 1 02:30 | +3.3%next day −3.8% · 5 days −6.3% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Prothena
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $26.33 at a price of $8.38 (+214.2%); now: $26.33 at $8.35 (+215.4%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 3 | 4 | 3 | 3 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 2 | 1 | 1 | 1 | 1 | 1 |
Earnings and sales forecast
Next report: 29.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.23 (from $-0.38 to $0.57). Last quarter: $-0.36.
Sales
Next quarter’s sales estimate — $10M (from $0M to $55M). Last quarter: $1M.
Best top-analyst consensus in the sector · Healthcare
About Prothena
- CEO: Gene G. Kinney
- Employees: 67
- 77 Sir John Rogerson’s Quay, Dublin, DU, D02 VK60, IE
- www.prothena.com
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
Data from the stock’s TipRanks forecast page, read 136 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗